Sorry, you need to enable JavaScript to visit this website.
Who we Are

Transparency

Bayer Cross

For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.

The patient comes first

Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.

 

Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.

 

Our principles

Cooperation between Bayer and patient organizations is based on the following principles.

  1. In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
    • raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
    • understanding diseases and making sure that patients receive the best medical treatment available,
    • improving the information provided to the patients,
    • supporting medical innovations.
  2. Bayer and the patient organizations comply with international and national laws and regulations.
  3. Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
  4. Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.

 

Overview of cooperation with patient organizations in Europe in 2018

The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2018.

Patient Organizations Country of Organization's Office Nature and Purpose of Support Value in Local Currency Value in Euro Travel costs in EURO
International Diabetes Federation (IDF) Belgium Contribution to IDF's efforts to improve the life of people living with diabetes   30,000.00 no
Asociacion de Hemofilia de la Communidad Valencia Spain Support activities of PO regarding their educational activity "Cycling for Hemophilia 2018"   40,000.00 no
IAPB (International Agency for the Prevention of Blindness) UK Support of patron level membership 100,000.00 USD 88,398.70 no
International Agency for the Prevention of Blindness (IAPB) UK Support of PO regarding their World Sight Day Photo Competition 2018, October 11, 2018 30,000.00 USD 26,519.60 no
European Pulmonary Hypertension Association (PHA Europe) Austria Support of PO regarding the distribution of educational materials for patients on a novel nebulizing device "Breelib"   50,000.00 no
Federation of European Scleroderma Associations (FESCA) Belgium Support of PO in organizing their World Scleroderma Day (WSD) in 2018 and Campaign Conceptualization   25,000.00 no
European Pulmonary Hypertension Association (PHA Europe) Austria Support of PO's activities in 2018   100,000.00 no
EURORDIS (European Rare Diseases Organisation) France One-year membership of the PO’s "Round Table of Companies"   5,000.00 no
Stroke Alliance for Europe (SAFE) UK Support of PO in organizing the SAFE Working Conference and General Assembly November 27-30, 2018, Berlin, Germany   90,000.00 no
European Pulmonary Hypertension Association (PHA Europe) Austria PO's representatives provide consultancy and advisory service on production of patient videos regarding Patient Advocacy/Pulmonary Hypertension   7,800.00 644.00
Stroke Alliance for Europe (SAFE) UK Support of PO in organizing the "Stroke Education and Training Programme" in 2018   334,056.00 no
EHC (European Haemophlilia Consortium) Belgium One-year membership of the PO’s Corporate Giving Program. One-year membership of the EHCs Round Tables.   45,000.00 no
EHC (European Haemophlilia Consortium) Belgium Support of PO regarding their Annual Conference, October 5-7, 2018, Brussel, Belgium   37,000.00 no
Country More Information  
Austria Country website

 

Baltic States Reports can be received from UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania) 
Alina Tikuišiene MD
Zirmunu str. 68A 
LT-09124 Vilnius/Lithunia
Belgium/Luxemburg (French) Country website  
Belgium/Luxemburg (Dutch) Country website  
Bulgaria Country website  
Croatia Country website  
Czech Republic Country website  
Denmark Country website  
Estonia Reports can be received from UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
LT-09124 Vilnius/Lithunia
Finland Country website  
France Country website  
Germany Country website  
Greece Country website  
Hungary Country website  
Iceland Reports can be received from Bayer AB- Bayer Scandinavia
Iina Wargh
Gustav III:s Boulevard 56
169 26 Solna
Ireland Country website  
Italy Country website  
Latvia Country website  
Lithuania Country website  
Netherlands Country website  
Norway Country website  
Poland Country website  
Portugal Country website  
Romania Reports can be received from SC Bayer SRL
Bayer Pharmaceuticals Division
Sos. Pipera nr. 42., Sector 2
NUSCO Tower fl. 1,16,17
020112, Bucharest
Romania
Serbia Reports can be received from Bayer Pharma d.o.o. 
Jelena Tokanovic
Omladinskih brigada 88b
Belgrade
Slovenia Reports can be received from Bayer d.o.o. 
Lucija Zlodi Gosnik
Bravnicarjeva 13
1000 Ljubljana
Slovakia Country website  
Spain Country website  
Sweden Country website  
Switzerland Country website  
Turkey Country website  
UK Country website  
Ukraine Country website